Abstract library

11 results for "Nobili".
#1724 Outcomes of Hepatobiliary Neuroendocrine Neoplasms Treated with Systemic Therapy: A Retrospective Analysis.
Introduction: Primary hepatobiliary neuroendocrine neoplasms (NEN) are rare. Knowledge about clinicopathological findings and treatment results of hepatobiliary NEN is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Komiyama Satoshi
#608 Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)?
Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors: Kim S, ...
Keywords: NEC, octreotide, GEP, HB
#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Francesca Spada
#415 Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
Introduction: A phase II study was designed to assess the activity and safety of metronomic oral capecitabine, bevacizumab, and octreotide (Xelbevoct) in metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). We also assessed the predictive role for progression free survival (PFS) of hypertension, proteinuria and vascular endothelial growth factor (VEGF) polymorphisms and the predictive role of vitamin D on proteinuria and PFS.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi
Keywords: bevacizumab
#694 Platinum-Based Chemotherapy for the Treatment of High-Grade Gastrointestinal and Unknown Primary Neuroendocrine Neoplasms
Introduction: Poorly differentiated neuroendocrine carcinomas (NEC sec. WHO 2010) are rare and aggressive neoplasms arising from different districts throughout the body. Platinum and etoposide regimen has been the most widely used first line treatment in this setting.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Marco Paragona
#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: Oxaliplatin, NETs
#1926 Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE)
Introduction: RGETNE is a national hospital-based GEP-NENs registry coordinated by the Spanish multidisciplinary scientific society GETNE.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD-PhD Paula Jimenez Fonseca
#2010 A case of Carcinoid Crisis Despite High Dose Somatostatin Analogue Therapy Peri-operatively
Introduction: Carcinoid crisis is a life threatening endocrine emergency. Somatostatin analogues (SSA) are recommended as prophylactic administration before invasive procedures. It remains unclear whether there is an optimal dose of prophylactic somatostatin analogue therapy in the peri-operative period.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Deborah Pitfield
Authors: Pitfield D, Casey R T, Seetho I, Shaw A, ...
#2117 Neuroendocrine Tumors: An Australian Experience
Introduction: Neuroendocrine tumours (NETs) in Australia are rare, but are rising in incidence.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Vivek Ashoka Menon
#2145 Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience
Introduction: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of neoplasms associated with paraneoplastic syndromes. Venous thromboembolism (VTE) is a frequent complication in neoplastic patients and it is associated with increased morbidity and mortality. To date, there have been no specific studies in NEN, except for glucagon-secreting tumors
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Federica Alessandra Cavalcoli